PMID- 25042878 OWN - NLM STAT- MEDLINE DCOM- 20150528 LR - 20240213 IS - 1879-0887 (Electronic) IS - 0167-8140 (Print) IS - 0167-8140 (Linking) VI - 112 IP - 1 DP - 2014 Jul TI - EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. PG - 30-6 LID - S0167-8140(14)00270-9 [pii] LID - 10.1016/j.radonc.2014.06.012 [doi] AB - PURPOSE: We investigated whether expression of epidermal growth factor receptor (EGFR) was associated with survival and disease control in this secondary analysis of a phase II trial of cetuximab+chemoradiation for stage III non-small cell lung cancer. METHODS: Patients received cetuximab weekly before and during radiation (63 Gy/35 fractions/7 weeks) with weekly carboplatin + paclitaxel. We analyzed EGFR expression by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in pretreatment biopsy specimens and compared findings with overall and progression-free survival (OS, PFS) and time to progression (TTP). RESULTS: Specimens for IHC and FISH were collected from 51 and 45 of 87 evaluable patients. Pretreatment characteristics did not differ for patients with (n = 51) or without (n= 36) EGFR IHC data, or with (n = 45) or without (n = 42) FISH data. However, patients without IHC data had worse OS (HR = 1.63, P = 0.05), worse PFS (HR = 1.88, P = 0.008), and worse TTP [HR = 1.99, P = 0.01] than those with IHC data. EGFR protein expression was not related to pretreatment characteristics or OS; FISH-positive disease was associated with better performance status but not with OS, PFS, or TTP. CONCLUSIONS: Surprisingly, outcomes differed not by EGFR expression but by the availability of samples for analysis, underscoring the importance of obtaining biopsy samples in such trials. CI - Copyright (c) 2014 Elsevier Ireland Ltd. All rights reserved. FAU - Komaki, Ritsuko AU - Komaki R AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. Electronic address: rkomaki@mdanderson.org. FAU - Paulus, Rebecca AU - Paulus R AD - RTOG Statistical Center, Philadelphia, United States. FAU - Blumenschein, George R Jr AU - Blumenschein GR Jr AD - Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. FAU - Curran, Walter J Jr AU - Curran WJ Jr AD - Winship Cancer Institute of Emory University, Atlanta, United States. FAU - Robert, Francisco AU - Robert F AD - University of Alabama at Birmingham Comprehensive Cancer Center, United States. FAU - Thariat, Juliette AU - Thariat J AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. Electronic address: jthariat@hotmail.com. FAU - Werner-Wasik, Maria AU - Werner-Wasik M AD - Thomas Jefferson University Hospital, Philadelphia, United States. FAU - Choy, Hak AU - Choy H AD - The University of Texas Southwestern, Dallas, United States. FAU - Hirsch, Fred R AU - Hirsch FR AD - University of Colorado Cancer Center, Aurora, United States. FAU - Ang, Kie Kian AU - Ang KK AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States. LA - eng GR - U10 CA180868/CA/NCI NIH HHS/United States GR - P01 CA006294/CA/NCI NIH HHS/United States GR - U10 CA21661/CA/NCI NIH HHS/United States GR - U10 CA37422/CA/NCI NIH HHS/United States GR - U10 CA037422/CA/NCI NIH HHS/United States GR - U10 CA021661/CA/NCI NIH HHS/United States GR - P01 CA06294/CA/NCI NIH HHS/United States GR - U10 CA180822/CA/NCI NIH HHS/United States GR - U10 CA032115/CA/NCI NIH HHS/United States GR - P30 CA016672/CA/NCI NIH HHS/United States GR - U10 CA32115/CA/NCI NIH HHS/United States PT - Clinical Trial, Phase II PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20140716 PL - Ireland TA - Radiother Oncol JT - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology JID - 8407192 RN - 0 (Antibodies, Monoclonal, Humanized) RN - BG3F62OND5 (Carboplatin) RN - EC 2.7.10.1 (ErbB Receptors) RN - P88XT4IS4D (Paclitaxel) RN - PQX0D8J21J (Cetuximab) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antibodies, Monoclonal, Humanized/administration & dosage MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Carboplatin/administration & dosage MH - Carcinoma, Non-Small-Cell Lung/*metabolism/mortality/therapy MH - Cetuximab MH - Chemoradiotherapy MH - Disease-Free Survival MH - ErbB Receptors/*metabolism MH - Female MH - Humans MH - Immunohistochemistry MH - In Situ Hybridization, Fluorescence MH - Lung Neoplasms/*metabolism/mortality/therapy MH - Male MH - Middle Aged MH - Paclitaxel/administration & dosage MH - Prognosis MH - Treatment Outcome PMC - PMC4169722 MID - NIHMS611299 OTO - NOTNLM OT - Cetuximab OT - Clinical trials identifier NCT00081302 OT - Erbitux OT - Inoperable lung cancer OT - RTOG 0324 COIS- Conflict of Interest Notification: The authors declare no conflicts of interest. EDAT- 2014/07/22 06:00 MHDA- 2015/05/29 06:00 PMCR- 2015/07/16 CRDT- 2014/07/22 06:00 PHST- 2014/03/24 00:00 [received] PHST- 2014/06/12 00:00 [revised] PHST- 2014/06/15 00:00 [accepted] PHST- 2014/07/22 06:00 [entrez] PHST- 2014/07/22 06:00 [pubmed] PHST- 2015/05/29 06:00 [medline] PHST- 2015/07/16 00:00 [pmc-release] AID - S0167-8140(14)00270-9 [pii] AID - 10.1016/j.radonc.2014.06.012 [doi] PST - ppublish SO - Radiother Oncol. 2014 Jul;112(1):30-6. doi: 10.1016/j.radonc.2014.06.012. Epub 2014 Jul 16.